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Abstract 
Forkhead box O (FoxO) transcription factors play important roles in cellular 
physiology and biology. Recent findings indicate that FoxOs are also involved in the 
development of major depressive disorder. Alterations in the upstream molecules of 
FoxOs, such as brain derived neurotrophic factor or protein kinase B, have been 
linked to depression. Antidepressants, such as imipramine and venlafaxine, modify 
the FoxOs phosphorylation. Furthermore, FoxOs could be regulated by serotonin and 
norepinephrine receptor signaling as well as the hypothalamic-pituitary-adrenal axis, 
all of which are involved in the pathogenesis of depression. FoxOs also regulate 
neuronal morphology, synaptogenesis and adult hippocampal neurogenesis, which are 
viewed as candidate mechanisms for the etiology of depression. In this review, we 
emphasize the possible roles of FoxOs during the development of depression and 
make some strategic recommendations for future research. We propose that FoxOs 
and its signaling pathways may constitute potential therapeutic targets in the treatment 
of depression. 
 
Keywords: FoxO, major depression, PI3K/Akt, neuronal atrophy, neurogenesis, 
antidepressants 
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1. Introduction 
Major depression is one of the most severe and common psychiatric disorders 
with high rates of self-harm and suicide attempts (Hegerl et al., 2013). The causes of 
major depressive disorder are not well understood. A diverse contribution of genetic, 
neurochemical and environmental factors are involved in the onset and progression of 
depression. Besides the common monoamine hypotheses, the diathesis stress model is 
another attempt to explain the etiology of depressed behavior (Gold and Chrousos, 
2013). Diathesis interacts with the subsequent stress response of an individual, 
especially some early life experiences which are known to increase the risk for 
depression (Kiejna et al., 2010). Antidepressants initially correct imbalances of 
neurotransmitters in the synapse cleft (Mahar et al., 2014; Werner and Coveñas, 2013), 
while the therapeutic response may result from above and the downstream adaptive 
changes that occur as a consequence of increased neuroplasticity. These subcellular 
events include synaptic transmission, gene expression, neuronal morphological 
changes and many other molecular events in the brain (Kavalali and Monteggia, 2012; 
Pilar-Cuéllar et al., 2012; Seo et al., 2014). However, some patients do not tolerate  
some of the undesirable effects associated with these agents such as nervousness, 
insomnia or sexual dysfunction (Sussman. 1994). Novel targets and new classes of 
antidepressant agents are required to improve the therapeutic arsenal for the treatment 
of depression. In addition, currently available antidepressants are prescribed for both 
moderately and severely depressed patients (Fournier et al., 2010), and for severe 
major depression, a combination of antidepressant medication and psychotherapy or 
electroconvulsive therapy are usually considered (Oudega et al., 2011; Hollon et al., 
2014). Antidepressants have unusual temporal responses with many agents having a 
delayed onset of action since clinical improvement is observed several weeks after 
initiation of antidepressant drug and usually patients have to take antidepressants for 
months to get a stable maximal improvement (Kirsch et al., 2008; Mitchell. 2006). 
Antidepressants require a timescale of minutes to boost the synaptic concentration of 
serotonin and/or norepinephrine, whereas the onset of the therapeutic action is usually 
a few weeks after the initiation of therapy. The traditional view about the delayed 
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onset of current antidepressant action relies on neurobiological effects that develop 
slowly under chronic drug treatment, such as alterations of glucocorticoid receptor 
systems in patients with depression, and changes of gene and protein expression 
related to dendritic spines, production of brain derived neurotrophic factor (BDNF), 
adult hippocampal neurogenesis and enhanced synaptic plasticity (Hajszan et al., 2005; 
Anacker et al., 2011b; Malberg et al., 2000; Groves. 2007). The pathological 
mechanisms of depression need to be further explored and the controversy about the 
mechanism of current antidepressant agents to be resolved.  
In recent years, the regulation of gene expression has been implicated in the 
etiology and treatment of depression; several genes such as BDNF, fibroblast growth 
factor receptor 1, NCAM1 neural cell adhesion molecule 1, and 
Calcium/Calmodulin-dependent Protein Kinase II have been identified to be of 
interest (Groves. 2007; Tochigi et al., 2008). Transcription factor DNA binding 
peptides are essential for the regulation of gene expression and are themselves 
regulated by phosphorylation and dephosphorylation. For example, phosphorylated 
cAMP-response element binding protein (CREB) transcription factor binds to the 
regulatory site on the BDNF promoter and increases BDNF protein levels, both of 
which have been associated with depression (Breuillaud et al., 2012). Transcription 
factors could serve as the intermediates between intracellular signaling cascades and 
gene expression, and therefore be involved in the pathophysiology of depression and 
represent potential targets for the pharmacotherapy. 
Forkhead box O (FoxO) is a transcription factor, which plays a regulatory role in 
multiple biological and pathological systems, including the central nervous system 
(CNS). Recent discoveries indicate a role for FoxO in the pathogenesis of  
depression and other psychiatric disorders (Polter et al., 2009; Weeks et al., 2010; 
Zheng et al., 2013). Enhanced neurotrophins or serotonin neurotransmission in animal 
brain phosphorylate and inactivate FoxO3a (Zheng et al., 2002; Polter et al., 2009). 
BDNF, which is reduced in depression (Karege et al., 2005; Angelucci et al., 2005), 
promotes phosphorylation of the FoxO protein (Mojsilovic-Petrovic et al., 209; Zhu et 
al., 2004); moreover, FoxO3a-deficient mice display an antidepressant-like behavior 
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(Zheng et al., 2002; Polter et al., 2009; Zheng and Quirion, 2004); Furthermore, both 
the serotonin-norepinephrine reuptake inhibitor antidepressant venlafaxine and the 
mood stabilizer lithium, suppress FoxO3a activity in mouse brain (Wang et al., 2013; 
Mao et al., 2007). FoxOs are under the control of neurotransmitters (Liang et al., 2006) 
and glucocorticoids(Qin et al., 2014). FoxOs also regulate signals for cellular atrophy 
(Jaitovich et al., 2015), cellular morphology (Aranha et al., 2009) and  adult 
neurogenesis (Zhang et al., 2013) and all of these physiological or pathological 
conditions contribute to the development of depression (Borre et al., 2014; Mahar et 
al., 2014; Anacker et al., 2013). Although the role of FoxOs in the process of 
depression is only beginning to be unveiled, it is reasonable at this time to 
hypothesize that FoxO transcription factors will be found to be pivotal mediators in 
psychiatric disorders. In this review, cellular signaling cascades responsible for 
regulating FoxOs, the possible roles of FoxOs in the development of depression, the 
effects of antidepressants on the activity of FoxOs as well as the potential mechanistic 
pathways linking major depression and FoxOs will be discussed.  
2. Overview of FoxO signaling pathway 
Forkhead box (Fox) proteins are a family of transcription factors characterized 
by a conserved “forkhead” or “winged helix” DNA binding motif. Foxs bind to the 
regulatory sequence of the downstream target genes and play important roles in 
regulating the transcription of genes involved in cell growth, proliferation, 
differentiation, metabolism, apoptosis and drug resistance (Lam et al., 2013; Accili 
and Arden 2004). According to the sequence homology, Fox superfamily genes can be 
classified from FoxA to FoxS (Lam et al., 2013). Of the Fox subfamilies, the FoxO 
group is one of the most researched subgroups. FoxOs share a conserved 
DNA-binding domain, the binding sequence is 5’-TTGTTTAC-3’ (Brent et al., 2008). 
In mammals, there are four FoxO homologues, FoxO1, FoxO3a, FoxO4 and FoxO6. 
FoxO2 was shown to be same with FoxO3a and FoxO5 is the ortholog of FoxO3a in 
the zebra fish (Carter and Brunet, 2007). The activity of FoxO is regulated by 
post-translational modification, including phosphorylation, acetylation, methylation, 
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ubiquitination and glycosylation (Eijkelenboom and Burgering, 2013; Zhao et al., 
2011). Phosphorylation of FoxO by protein kinases has been extensively studied. 
Protein kinase B (Akt), serum/glucocorticoid inducible kinase (SGK), AMP-activated 
protein kinase (AMPK), mitogen-activated protein kinases (MAPK), inhibitor of 
nuclear factor kappa-B kinase (IKK), cyclin-dependent kinase (CDK) and mammalian 
sterile 20-like kinase (MST) are common upstream kinases for FoxO (Boccitto and 
Kalb, 2011). Phosphatidylinositol 3-kinase (PI3K)/Akt signal pathway activated by 
insulin or growth factors mediates the major regulation of FoxO (woodgett, 2005). 
Binding of insulin or other growth factors (such as nerve growth factor, BDNF or 
insulin like growth factor 1 (IGF-1) to their receptors leads to the autophosphorylation 
of the growth factor receptor and its subsequent activation (Zheng et al., 2002; Zheng 
and Quirion, 2004; Zheng and Quirion, 2009). Through regulation via the PI3K/Akt 
pathway, many of downstream target genes of FoxO (such as Btg-1, Bim-1, FasL, 
MnSOD, p27, PEPCK) are regulated and these gene products play roles in cell 
proliferation (p27), differentiation (Btg-1), metabolism (PEPCK) , apoptosis (Bim-1, 
FasL) and drug resistance (Wen et al., 2012; van der Vos and Coffer, 2011; Hui et al., 
2008). For example, sustained FoxO3a activation promotes drug resistance by 
activating and promoting the expression of ATP-binding cassette sub-family B 
member 1, which is a plasma membrane P-glycoprotein that functions as an efflux 
pump for various anticancer agents, including doxorubicin (Hui et al., 2008). 
The PI3K pathway is a major regulator of FoxOs activity. Akt and SGK are two 
key downstream components of the PI3K pathway and both of them recognize the 
RXRXXS/T motif. Akt phosphorylates FoxO3a at Thr32, Ser253 and Ser315, while 
SGK phosphorylates FoxO3a at Thr32 and Ser315. For FoxO1, Akt phosphorylates it 
at Thr24, Ser256 and Ser319, while SGK phosphorylates it at Thr24 and Ser319 
(Burgering and Kops, 2002). Phosphorylation of these sites leads to translocation of 
FoxOs from the nucleus to cytoplasm and inhibition of transcriptional activity (Chen 
et al., 2013; Huang and Tindall, 2007). What is important is that the C terminal of 
FoxO6 lacks the Akt phosphorylation site and thus it is constitutively nuclear (Jacobs 
et al., 2003). Extracellular regulated protein kinase (ERK) is a downstream 
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component of MEK and it has been shown to phosphorylate FoxO3a at Ser294, 
Ser344 and Ser425 (Yang et al., 2008), similarly, activation of IKK induces FoxO3a 
phosphorylation at Ser644 (Hu et al., 2004). Phosphorylation of FoxO3a by both ERK 
and IKK leads to nuclear exclusion and degradation. The serine/threonine kinases p38 
and c-Jun N- terminal kinase (JNK) are other two major MAPK pathways relevant to 
FoxO function. p38 phosphorylates FoxO3a at Ser7 and promotes the nuclear 
translocation and activation of FoxO3a (Ho et al., 2012); JNK may repress the 
PI3K/Akt signal pathway, thereby activating FoxO3a indirectly, meanwhile, it may 
phosphorylayte FoxO proteins in a direct way (Sunters et al., 2006). FoxOs may also 
play a critical role in the regulation of energy homeostasis when phosphorylated by 
the AMP-activated protein kinase (AMPK) at six sites (Greer et al., 2009). In contrast 
to the effect of the above kinases on FoxOs, MST binds to FoxO3a and 
phosphorylates it at Ser207; however, the phosphorylation of this site promotes its 
nuclear accumulation and subsequently the expression of proapoptotic genes (Sanphui 
and Biswas, 2013). Another interesting example is the role of CDK on FoxOs. CDK1 
phosphorylates FoxO1 at Ser249 and enhances the content of FoxO1 in the nucleus 
and thus promotes cell death (Yuan et al., 2008), CDK2 phosphorylates FoxO1 at the 
same site, however, it leads to the accumulation of FoxO1 in the cytoplasm and the 
inhibition of FoxO1 (Huang et al., 2006). Figure 1 summarizes the above pathways 
regulating FoxO activity and subcellular localization.  
 
Fig.1. Effects of various upstream regulators on the activity and subcellular localization of 
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FoxO. Phosphorylation is one of the most common post-translational modifications. Kinases, such 
as Akt, IKK, SGK, ERK1/2 and CDK promote the export from the nucleus and inactivation of 
FoxO. While under stress conditions, MST, AMPK, p38MAPK and JNK induce the nuclear 
accumulation and activation of FoxO. In the nuclear, FoxO recognizes and binds to  FRE (FoxO 
response element), activated FoxO thereby regulates the transcription activity of its downstream 
targets, which makes it possible to regulate many cellular processes, including proliferation, 
differentiation, metabolism, apoptosis and drug resistance. 
3. FoxO expression patterns in the brain  
FoxO is one of the substrates for Akt which is a pro-survival serine/threonine 
kinase. The PI3K/Akt signal pathway plays a critical role in mediating neuronal 
survival. FoxO regulates the expression of genes involved in neuronal cell apoptosis 
and oxidative stress, such as Bim-1, FasL, Catalase and MnSOD (Brunet et al., 2001a, 
Wen et al., 2012). The pattern of protein distribution related to FoxO functions points 
to the associated biological functions. Understanding the expression patterns of FoxO 
in the CNS should help us to understand the relationship between FoxO and 
neurodevelopment, neurodegeneration and potentially neuropsychiatric disorders. 
FoxOs are highly expressed in brain areas related to the regulation of mood and stress. 
FoxO1, FoxO3a and FoxO4 are each expressed during neurodevelopment and also in 
the adult, with distinct patterns ranging from ubiquitous to tissue-specific (Biggs et al., 
2001). Among the FoxO subtypes expressed in brain, FoxO1 is mostly expressed in 
the hippocampus and the striatum (Zemva et al., 2012), its mRNA is expressed in part 
of the ventral region of the CA3 pyramidal neurons, however, no expression was 
observed in the dorsal CA3 neurons (Hoekman et al., 2006). FoxO3a shows the 
widest brain expression, whereas FoxO4 is expressed at very low levels in the brain 
and a FoxO4 probe did not reveal detectable expression in the adult murine brain 
(Salih et al., 2012). FoxO6 is mostly expressed during the developmental stage with a 
nuclear-predominant distribution (Jacobs et al., 2003). For FoxO6, both the protein 
and mRNA levels are highly expressed during the stage of neuronal development, and 
its expression decreases during maturity but then stays relatively constant. In the adult 
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brain, FoxO6 protein is expressed abundantly in hippocampus, amygdala and nucleus 
accumbens (Salih et al., 2012). Converging evidences suggest that the hippocampal 
complex may play a role in the pathology of major depression (Campbells and 
Macqueen, 2004). FoxO isoforms also have different patterns of expression in the 
hippocampus where FoxO1 is enriched in the dentate gyrus (DG) region of 
hippocampus, FoxO3a is present in all hippocampal areas but more highly expressed 
in the DG and CA3 regions than in the CA1 region. FoxO6 is enriched in the CA1 and 
CA3 hippocampal areas (Hoekman et al., 2006; Furuyama et al., 2000; Jacobs et al., 
2003; Salih et al., 2012). The differential expression patterns suggest that FoxO 
isoforms may have specific and perhaps complementary or redundant roles in 
different physiological or pathological processes. In conclusion, spatial expression 
patterns of FoxO gene family members in the CNS, especially regions related to stress, 
implicate their biological functions in stress-related behavior regulation.  
4. FoxOs regulate the behavioral manifestation of depression 
The role of FoxOs in psychiatric disorders has recently drawn more attention 
even though the data in this area are somewhat limited at this time. FoxOs, especially 
FoxO6, are expressed abundantly in hippocampus, amygdala and nucleus accumbens  
which are important brain areas involved in aversive and rewarding responses to 
emotional stimuli (Accili and Arden, 2004; Hoekman et al., 2006). Thus FoxOs could 
mediate the inability to experience pleasure and lack of motivation that predominate 
in many patients with depression (Berton and Nestler, 2006). The subregional 
distributions of FoxOs could predict their roles in the regulation of mood and emotion. 
In a case-control association study in a Brazilian population, FoxO3a emerged as an 
gene candidate involved in bipolar disorder and related behaviors. Three 
single-nucleotide polymorphisms within the FoxO3a gene (rs1536057, rs2802292 and 
rs1935952) were associated with bipolar disorder (Magno et al., 2011). Mood-related 
behavioral disturbance, such as depression, is highly related to stress (Krishnan and 
Nestler, 2008). In a learned helplessness animal model, which is a commonly used 
model to mimic human depression (Muller et al., 2011), inescapable shocks 
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significantly reduced the phosphorylation of FoxO3a and induced the nuclear location 
of FoxO3a in the cerebral cortex, interestingly, learned helplessness behavior was 
markedly diminished in FoxO3a-deficient mice(Zhou et al., 2012). This research 
provides evidence that depression activates FoxO3a. These results was consistent with 
the previous report that FoxO3a influences behavioral processes linked to anxiety and 
depression and FoxO3a-deficient mice show a significant antidepressant-like behavior, 
but these animals didn't exhibit changes in general locomotor activity tested by open 
field test (Polter et al., 2009), suggesting that FoxO3a is a transcriptional target for 
mood disorder treatment. In contrast, a study using a knockout (KO) mause model 
suggested that FoxO1 KO mice displayed reduced anxiety (Polter et al., 2009). 
Recently, disrupted rhythms are observed in psychiatric disorders, including 
depression (Emens et al., 2009). Association of Clock gene and major depressive 
disorder has also been suggested (Germain and Kupfer, 2008). Although the detailed 
etiologies still need to be unraveled, it is evident that there is a strong relationship 
between major depression and circadian disruption (Karatsoreos, 2014). Interestingly, 
clock is a transcriptional target of FoxO3a and the insulin-FoxO3a-Clock signaling 
pathway plays a key role in the modulation of circadian rhythms, for instance, knock 
down of FoxO3a dampens circadian amplitude (Chaves et al., 2014; Zheng et al., 
2007). These studies revealed an important new role for FoxOs in the regulation of 
depressive behavior. 
BDNF is a well known regulator involved in the pathophysiology of mood 
disorders and a recognized upstream effector of FoxOs. The role of BDNF in 
depression is well characterized. Depression, at least in its severe form, is associated 
with reduced neuronal plasticity and lower levels of BDNF, while antidepressants, 
such as fluoxetine, could reactivate BDNF-mediated neuronal plasticity (Castrén and 
Rantamäki, 2010). BDNF reduces FoxO transcriptional activity through activation of 
TrkB and downstream kinases including Akt, which is a candidate susceptibility gene 
related to schizophrenia (Emamian et al., 2004). The link between Akt and depression 
was also provided by both genetic studies and postmortem data (Hsiung et al., 2003; 
Pereira et al., 2014). In response to BDNF, active Akt phosphorylates and inactivates 
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FoxOs (except for FoxO6, which is constitutively nuclear) by facilitating their 
translocation out of the nucleus (Wen et al., 2012). In both invertebrate and vertebrate 
brain, FoxOs can be phosphorylated and inactivated by serotonin selective reuptake 
inhibitors or exogenous serotonin via a PI3K/Akt-dependent mechanism (Polter et al., 
2009; Liang et al., 2006). All of data suggests that downregulation or inactivation of 
FoxOs are highly related to antidepressant-like effects. 
5. Antidepressants regulate the activities of FoxOs 
The classical view of depression is that a functional deficit in neurotransmitters, 
particularly decreased levels of serotonin and noradrenaline, are associated with the 
clinical symptoms of depression. Serotonin could be viewed as a regulator of the 
insulin/IGF-1-FoxO pathway in stress physiology and modulation of FoxO by 
serotonin represents a conserved feature of stress physiology. Acute stressful life 
events can lead to the recurrence of episodes of major depression and chronic stress is 
strongly associated with both onset and recurrence of depression (Kessler, 1997; 
Risch et al., 2009). Studies of C. elegans showed that serotonin-deficient mutants 
exhibited DAF-16 (the homologues of FoxO) nuclear accumulation in constitutive 
physiological stress states, while treatment with exogenous serotonin directly or with 
fluoxetine, an antidepressant known to increase synaptic levels of endogenous 
serotonin, prevented DAF-16 nuclear accumulation in wild-type animals under 
aversive conditions (Liang et al., 2006). This result was confirmed by experiments 
showing that serotonin and fluoxetine can partially suppress DAF-16 nuclear 
accumulation in wild type animals exposed to hypergravity in C elegans (Kim et al., 
2007). These observations suggest that individual behavior and physiological or 
psychiatric responses to the environment in animals are likely accompanied by the 
changes of the subcellular location/function of FoxO protein.  
The tricyclic antidepressant agent, imipramine, is a monoamine-regulating 
antidepressant. Chronic treatment with imipramine for 28 days in mice caused 
appreciable increases in phosphorylated FoxO1 (Ser256), FoxO3a (Ser253) and Akt 
(Thr308) in the cerebral cortex, hippocampus and striatum, but no changes in the level 
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of total FoxO1, FoxO3a and Akt were observed (Polter et al., 2009). Our previous 
results also indicated that the FoxO3a subtype in PC12 cells could be inactivated by 
the antidepressant venlafaxine via PI3K/Akt pathway. Venlafaxine, on one hand, 
induced the phosphorylation of Akt and FoxO3a by the PI3K/Akt pathway and on the 
other hand reversed the reduction of phosphorylated Akt and FoxO3a and the nuclear 
translocation of FoxO3a induced by corticosterone (Wang et al., 2013). Lithium, 
another well known therapeutic drug in the treatment of mood disorder, reduced 
FoxO3a transcriptional activity, gene expression and protein levels in both the cytosol 
and nucleus, and this effect was independent of Akt (Mao et al., 2007). Moreover, this 
effect of lithium was observed in SH-SY5Y neuroblastoma cells and mouse brain 
(cortex and hippocampus) after relevant lithium treatments, which indicate that this 
effect is likely therapeutically relevant (Mao et al., 2007). Amphetamine is a 
compound which can increase the concentration of dopamine in the synaptic gap and 
thus induce hyperactivity, reversal of its action by lithium is used to model mania in 
bipolar disorder. A study from our lab indicated that pretreatment of animals with 
lithium prevented an amphetamine-induced decrease in striatal phosphorylated Akt 
and FoxO1 levels (Zheng et al., 2013). Lithium also attenuated amphetamine-induced 
locomotor activity and decreased prepulse inhibition (Zheng et al., 2013). The 
modulation by lithium of FoxO and its upstream kinases (such as Akt) may be 
relevant to the treatment of neuropsychiatric disorders. Since FoxO3a can be 
regulated by BDNF-induced Akt activation, and phosphorylated by antidepressants, 
we hypothesize that FoxO3a is a candidate transcription factor that plays a role in 
mood disorders, including depression. Further studies are needed to elucidate the role 
of FoxO transcription factors in the neuropathology and treatment of mood disorders. 
6. FoxO as a regulator of serotonin and norepinephrine signaling 
Decreased or abnormally low levels of serotonin and norepinephrine in the 
synaptic cleft is traditionally viewed as a common cause of mood disorders, including 
depression. These neurotransmitters play their roles by binding and activating their 
specific receptors. With the exception of the 5-HT3 receptor, which is a ligand-gated 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
ion channel, all other 5-HT receptors and adrenergic receptors are seven 
transmembrane G protein-coupled receptors (GPCRs) whose binding to serotonin or 
norepinephrine activates several intracellular second messenger cascades. Some of 
these cascades are related to FoxOs. For example, the serotonin 2A receptor 
(5-HT2AR) is highly expressed on pyramidal neurons in the frontal cortex and has 
been implicated in several psychiatric disorders, including depression. The density of 
5-HT2R is higher in depressive patients than that in normal persons. Higher 5-HT2A 
binding in the prefrontal cortical region has been shown to be associated with greater 
gene expression in depression and youth suicide (López-Figueroa et al., 2004). 
Antidepressants (such as mirtazapine and mianserin) could occupy 5-HT2AR, block 
its role and augment the clinical response to SSRIs (Celada et al., 2004). Serotonin 
binds to 5-HT2AR and stimulates Akt phosphorylation in the frontal cortex and in 
primary cortical neurons through the activation of a PI3K/Akt cascade (Schmid and 
Bohn, 2010). FoxO transcription factors are downstream targets of PI3K/Akt, which 
is mainly regulated by receptor tyrosine kinases (such as IGF-1 receptor) and GPCRs. 
Serotonin is a regulator of the insulin/IGF-1 pathway in stress physiology and 
exogenous 5HT can suppress the nuclear accumulation of FoxO in wild-type animals 
under stress (Liang et al., 2006). Moreover, in the peripheral system, serotonin also 
influences the physiological actions of FoxO, for example, serotonin enhances the 
proliferation of hepatocellular carcinoma cells through upregulation of FoxO3a 
(Liang et al., 2013) . Duodenum-derived serotonin is a critical regulator of bone mass 
during the process of bone formation, and importantly FoxO1 mediates this effect 
(Kode et al., 2012). High circulating serotonin levels prevent the association of 
FoxO1 with CREB, resulting in suppressed osteoblast proliferation (Kode et al., 2012). 
These results demonstrate that FoxO acts as an endogenous mediator of serotonin 
signaling which may have consequences for the role of FoxOs in psychiatric disorders 
associated with altered serotonin metabolism. 
As mentioned above, the 5-HT3 receptor is a ligand-gated ion channel whereas 
other receptors for serotonin are GPCRs. Serotonergic GPCRs can be classified on the 
basis of their associated Gα proteins into Gs-protein coupled receptors (5-HT4, 5-HT6, 
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5-HT7), Gi-protein coupled receptors (5-HT1, 5-HT5), and Gq/G11-protein coupled 
receptors (5-HT2). As for norepinephrine receptors, the adrenergic α1 receptor is a Gq 
coupled receptor whereas the adrenergic α2 is a Gi coupled receptor. Activation of 
Gs-protein coupled receptors leads to activation of adenylate cyclase and an increase 
in cellular levels of cAMP, while activation of Gi-protein coupled receptors results in 
decreased levels of cAMP. cAMP is a second messenger important in many biological 
processes, including mood/emotional regulation. Downstream effectors of cAMP 
include cAMP-dependent protein kinase (PKA) and exchange factor directly activated 
by cAMP (Epac). Deficits in cAMP/PKA or cAMP/ERK signaling are viewed as one 
of the mechanisms for the behaviorial symptoms in depression (Breuillaud et al., 2012; 
Musazzi et al., 2010). There is interplay between the PI3K/Akt/FoxO and cAMP/PKA 
signaling pathways (Chen et al., 2007). FoxO1 is a direct substrate for PKA and PKA 
phosphorylates FoxO1 at Thr24, Ser256, and Ser319, three known Akt 
phosphorylation sites (Lee et al., 2011). Epac is an exchange protein activated by 
cAMP. Both Epac and PKA induce ERK phosphorylation, and ERK in turn 
phosphorylates FoxO3a at Ser294, Ser344 and Ser425 (Yang et al., 2008), and FoxO1 
at Ser246, Ser284, Ser295, Ser326, Ser413, Ser415, Ser429, Ser467 and Ser475 
(Asada et al., 2007) resulting in degradation of FoxO proteins (Fig.2). These results 
show that the binding of ligands or agonists to the serotonin or norepinephrine 
receptors results in the alteration of intracellular cAMP, which affect the cAMP/PKA 
or cAMP/ERK signal pathway, and might influence the biological functions of 
FoxOs.  
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Fig.2. FoxO as a regulator of serotonin signaling. 5-HT receptor is a G protein coupled 
receptor, when 5-HT binds, the receptor activates the coupled G protein, which can diffuse along 
the membrane surface and directly activate PI3K/Akt signal pathway, leading to inactivation of 
FoxO proteins. On the other hand, 5-HT receptor may also stimulate adenylyl cyclase/PKA and 
Epac/ERK1/2 signal transduction, both PKA and ERK1/2 enhance the phosphorylation of FoxO, 
which lead to inactivation of FoxO. Catalytic subunit of PKA translocates into nuclear and 
promote the activation of CREB, which is also highly related with depression. 
7. FoxO as an effector of Hypothalamic-pituitary-adrenal axis 
The activated hypothalamic-pituitary-adrenal (HPA) axis stimulates the secretion 
of adrenocorticotrophic hormone (ACTH) from the pituitary, which ultimately 
promotes the secretion of glucocorticoids from the adrenal cortex. Depression has 
been associated with hyperactivity of the HPA axis and increased levels of 
glucocorticoid in the serum where continuously high glucocorticoid levels attenuate 
the responsiveness and number of glucocorticoid receptors on hippocampal granule 
cells thus leading to impaired negative feedback suppression of glucocorticoid 
secretion and an even higher level of circulating corticosteroid (Anacker et al., 2011a; 
Anacker et al., 2011b; Raison and Miller, 2003). A schematic presentation of how the 
amygdala and the hippocampus regulate the HPA axis and the stress response is 
presented in Figure 3. Recent evidence suggests that FoxO plays a crucial role in the 
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pathophysiological hyperactivity of the HPA axis (Lutzner et al., 2012； Lutzner et al., 
2012). Glucocorticoids activate FoxO signaling, and FoxO signaling is a major 
contributor to the mechanism of glucocorticoid-induced muscle atrophy (Sandri et al., 
2004; Zhao et al., 2007). FoxO1 and FoxO3a expression (both mRNA and protein) are 
up-regulated by glucocorticoid treatment in hippocampal neurons and muscle cells 
(Anacker et al., 2011a; Poulsen et al., 2011). Induction of FoxO3a expression requires 
glucocorticoid receptor-binding steroids and is reversed by concomitant treatment 
with the glucocorticoid receptor antagonist RU-486 (Lutzner et al., 2012). Importantly, 
recent data indicate that FoxO3a is a direct glucocorticoid receptor target, as there are 
two potential glucocorticoid response elements within the promoter region of FoxO3a. 
These glucocorticoid hormones may induce transcriptional activation of FoxO3a 
directly (Lutzner et al., 2012). These results indicate that glucocorticoids regulate 
FoxO3a on a transcriptional level. Further evidence indicates that glucocorticoids 
regulate FoxO3a post-translationally. Glucocorticoids induce the expression of SGK, 
a serine/threonine kinase and activation and phosphorylation of SGK (Thr-256, 
Ser-422) is dependent upon PI3K activity (Buse et al., 1999). Activated SGK can 
promote cell survival through phosphorylating FoxO3a at sites Thr-32 and Ser-253 
(Brunet et al., 2001b). When given in relatively high doses, glucocorticoids inhibit 
PI3K/Akt signaling, thereby reducing the phosphorylation of FoxO (Wang et al., 2013; 
Stitt et al., 2004). Moreover, consistent with the notion that overload of 
glucocorticoids is crucial to the development of depression (Anacker et al., 2013; 
Anacker et al., 2011b), antidepressant treatment antagonizes the role of 
glucocorticoids (Budziszewska et al., 2000; David et al., 2009) and additionally 
increases the level of phosphorylated FoxO3a and PI3K/Akt (Wang et al., 2013). 
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Fig. 3. Regulation of HPA axis by the amygdala and hippocampus in normal and stress 
conditions. The corticotropin-releasing hormone neurons are regulated by both the amygdala and 
the hippocampus. Activation of amygdala promotes the release of cortisol through HPA axis. 
Mineralocorticoid receptors and glucocorticoid receptors are abundant in the hippocampus, both 
of which respond to and regulate the level of cortisol in the serum by glucocorticoid negative 
feedback. In stress condition, inappropriate activation of the amygdala extensively stimulates the 
HPA axis, resulting in high level of cortisol in the body. Chronic exposure of hippocampus to 
excessive glucocorticoid leads to neuronal loss and morphological atrophy, and thus the negative 
feedback becomes weaken or disrupted, which leads to much higher level of cortisol. Chronic 
stress induces nuclear localization of GR, which binds to glucocorticoid response 
element (GRE) and promotes the transcription of FoxO, GR may also activate SGK 
and subseqently inhibit the activity of FoxO. 
8. FoxOs regulate neuronal morphology and possibly mediate neuronal atrophy 
Neuroimaging studies with magnetic resonance imaging scanning demonstrated 
that compared with healthy individuals, depressed patients had an increased volume 
of the lateral ventricles and smaller volumes of the basal ganglia, thalamus, 
hippocampus, and frontal lobe (Arnone et al., 2012). The decreased cerebral size may 
be attributed to the loss and atrophy of neurons. In fact, clinical and preclinical studies 
have revealed that prolonged stress and major depression are associated with 
decreased neuronal synapses, neuronal atrophy of the PFC and the hippocampus 
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(Duman and Aghajanian, 2012; Ota et al., 2014; Sheline et al., 2003; Sheline et al., 
1996). Compared with normal controls, depressed patients showed decreased cortical 
thickness, neuronal size, and neuronal and glial densities in the prefrontal cortical 
regions (Rajkowska et al., 1999), but the molecular mechanisms underlying these 
morphological alterations have not yet been identified.  
FoxO transcription factors are important mediators of the effects of 
IGF-1/PI3K/Akt signaling. Withdrawal of IGF-1 causes reduced size of white matter 
structures in brain due to a decreased numbers of axons (Beck et al., 1995), while 
overexpression of IGF-1 leads to increased brain size due to an increase in cell size 
and apparently in cell number (Carson et al., 1993). As FoxOs are important key 
mediators of insulin and IGF-1 signaling (Kennedy et al., 2013), it is possible that 
FoxOs mediates the effect of IGF-1 in this process. Since overexpression of FoxO3a 
leads to reduced brain size and a decrease in neural progenitor number 
(Schmidt-Strassburger et al., 2012) and consistently, decreased FoxO activity has been 
reported to result in larger brain size and increased neural progenitor proliferation 
(Paik et al., 2009; Renault et al., 2009). Akt, one of the pivotal upstream kinases 
regulating the function of FoxO, has been shown to play a role in regulating cell size, 
a response which shares mechanisms with cellular atrophy or hypertrophy.  
Constitutively active Akt increases muscle fiber size and prevents denervation 
atrophy in regenerating and adult rat muscle (Pallafacchina et al., 2002). In 2004, Stitt 
et al., (Stitt et al., 2004) reported that the IGF-1/PI3K/Akt pathway plays an important 
role in preventing skeletal muscle atrophy by inhibiting the expression of 
muscle-specific ubiquitin ligases MAFbx and MuRF1. Interestingly, this effect 
involves Akt-mediated inhibition of the FoxO transcription factors as mutation of 
FoxO1 attenuated the activation of Akt thereby preventing Akt-mediated inhibition of 
muscle atrophy(Stitt et al., 2004). This research extended the function of FoxO to the 
regulation of cellular atrophy and the role of FoxO in cell atrophy and hypertrophy 
has since been extensively studied. As in skeletal muscle, overexpression of FoxO3a 
also caused a significant reduction in cardiomyocyte size in mouse hearts in vivo and 
the induction of atrogin-1 by FoxO3a accounts for this effect (Skurk et al., 2005). The 
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role of FoxO transcription factors in mediating the muscle atrophy has been widely 
studied (Castets and Ruegg, 2013; Sanchez et al., 2014; Lee et al., 2012), however, 
the specific role of FoxO in neuronal atrophy is largely unknown. The four FoxO 
members found in humans, FoxO1, FoxO3a, FoxO4, and FoxO6, are all expressed in 
the CNS (Biggs et al., 2001; Salih et al., 2012). The IGF-1/PI3K/Akt signaling 
pathway is a key pathway for neuronal homeostasis (Rafalski and Brunet, 2011a). 
FoxOs are the classic downstream targets of the IGF-1/Akt pathway and both 
IGF-1/PI3K/Akt and FoxO have been identified in the regulation of cell atrophy. 
From this perspective, it is likely that FoxO mediates neuronal atrophy in the CNS 
and this effect is related to the etiology of depression. This speculation is worthy of 
further investigation potentially leading to a better understanding of the precise 
functions of FoxO transcription factors in the regulation of neuronal cell size and this 
might lead to the development of completely novel therapeutic approaches to the 
prevention or limitation of the morphological alterations that prevail in ageing and 
pathological states, such as depression and schizophrenia . 
9. FoxOs play a inhibitory role in neurogenesis and synaptogenesis 
Preclinical evidence showed that adult hippocampal neurogenesis may contribute 
to the mechanism of antidepressant drug action and BDNF is probably involved in 
this effect (Malberg et al., 2000; Guilloux et al., 2013; Sairanen et al., 2005). In fact 
BDNF has been implicated in regulating adult neurogenesis in the subgranular zone of 
the DG and is important for the regulation of the basal level of neurogenesis in adult 
mice (Lee et al., 2002; Waterhouse et al., 2012). FoxOs are downstream effector 
molecules of BDNF since BDNF activates a variety of signaling cascades, including 
PI3K/Akt, Ras/MAPK and cAMP/PKA pathways and activation of these pathways 
phosphorylates and inhibits the functioning of FoxOs (Kwon et al., 2011; de la 
Torre-Ubieta and Bonni, 2011). The regulatory effects of BDNF on FoxOs and its 
target genes play a significant role in the BDNF-mediated neurogenesis, neuronal 
survival and plasticity (Zhu et al., 2004). 
FoxO transcription factors coordinately regulate diverse pathways to govern 
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neural stem cell or progenitor cell homeostasis in the brain (Paik et al., 2009; Renault 
et al., 2009). Given the importance of neural stem cells and progenitor cells for the 
generation of new neurons, the role of FoxO in the regulation of neurogenesis from 
neural stem cells has attracted attention. Genetic manipulation producing a transgenic 
mice expressing a constitutively active FoxO3a leads to mice having smaller brains 
accompanied with a loss of neurons in the olfactory bulbs, the cortex, the striatum, 
thalamic regions, and most notably the DG (Schmidt-Strassburger et al., 2012). Both 
the olfactory bulbs and the DG region are the sites for neurogenesis in adult, whilst 
neurogenesis assessed in adult FoxO3−/− and FoxO3+/+ mice revealed that FoxO3a 
deficiency in vivo led to an appreciable increase in the production of new neurons in 
the olfactory bulbs (Webb et al., 2013). However, the role of FoxOs in adult 
hippocampal neurogenesis remains to be investigated. FoxOs are classic downstream 
substrate of Akt (Zheng et al., 2002), these findings were quite consistent with earlier 
investigations showing that inhibition of 3-phosphoinositide-dependent protein kinase 
1/Akt signaling reduces neurogenesis in neural progenitor cells, whereas constitutive 
activation of Akt or phosphatase and tensin homolog deletion promotes neurogenesis 
(Oishi et al., 2009; Gregorian et al., 2009). These results support the argument that 
FoxO negatively regulates neurogenesis in the brain. 
Reduced synaptogenesis could be observed in the prefrontal cortex and 
hippocampus of patients with depression whereas normal synptogenesis restores the 
synapse connections in the brain that may deteriorate under stress and depression 
(Bambico and Belzung, 2013). Mammalian target of rapamycin (mTOR) is a 
ubiquitous protein kinase involved in protein synthesis and synaptogenesis. Activation 
of mTOR by PI3K/Akt promotes protein synthesis and synaptogenesis (Ayuso et al., 
2010). However, FoxOs play a role in protein degradation (White et al., 2013). 
Moreover, it has been shown that FoxO1 inhibits mTOR signaling and protein 
synthesis. Activation of constitutively active FoxO1 reduces the phosphorylation of 
4E binding protein 1 (Thr-37/46) and by consequence the phosphorylation of the 
downstream protein p70S6 kinase leading ultimately to an attenuation of protein 
production (Southgate et al., 2007). This inhibition of protein synthesis affects 
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proteins (such as post-synaptic density protein 95 and synaptophysin) involved in 
synapse formation. On the other hand, recent studies suggest that the rapid-acting 
antidepressant and synaptogenic effects of ketamine are dependent upon mToR 
activity in the medial prefrontal cortex (Li et al., 2010). This finding fits our 
hypothesis well. As mentioned previously, FoxOs inhibit mTOR signaling (Southgate 
et al., 2007), under this condition, inactivation of FoxOs may be beneficial for the 
antidepressant effect of ketamine. Microtubule architecture in neurons is an essential 
element in the regulation of neuronal morphology and motility as well as 
synaptogenesis (Conde and Caceres, 2009). FoxO loss-of-function models display 
increased stability of microtubule and overexpression of wild-type FoxO moderately 
destabilizes microtubules (Nechipurenko and Broihier, 2012). Thus, it is conceivable 
that FoxOs negatively regulate synaptic microtubule stability and thus negatively 
regulate synaptogenesis. The roles of FoxOs in the regulation of cellular atrophy, 
neurogenesis and synaptogenesis are depicted schematically in Figure 4. 
 
Fig. 4. The roles of FoxOs in the regulation of cellular morphology. Neurotrophic factors or 
growth factors, such as BDNF or IGF-1, play a pivotal role in the maintenance of normal cellular 
morphology. IGF-1 binds to its receptor and activates several signaling pathways. FoxOs are the 
classic downstream targets of IGF-1/PI3K/Akt pathway. Both IGF-1/PI3K/Akt and FoxOs are 
involved in the regulation of cell size. Activated Akt phosphorylates and inactivates FoxO proteins, 
it also phosphorylate and activate mTOR, which subsequently phosphorylates eukaryotic 
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translational initiation factor 4E binding protein 1 (4E-BP1), 70kDa ribosomal protein S6 kinase 
(p70S6K), and thereby promotes protein translation. Active FoxOs suppress the phosphorylation 
of 4E-BP1 and p70S6 kinase and thus limit protein synthesis. In addition, FoxO transcription 
factors induce the expression of atrophy- related ubiquitin ligase atrogin-1 and cause cellular 
atrophy, this effect possibly account for the neural atrophy implicated in the process of depression. 
FoxO may also suppress neurogenesis through inhibiting Wnt signaling. Furthermore, 
FoxOs limit the stability of microtubules, all of which contribute to the morphological changes 
(such as neuronal atrophy, decreased neurogenesis and synaptogenesis) occurring in the depressed 
individuals. 
Down-regulated adult hippocampal neurogenesis and synaptogenesis in the 
prefrontal cortex and hippocampus have been linked to major depressive disorder. 
Chronic stress leads to decreased neuronal/progenitor cell proliferation within the 
specific region of the brain, neuronal spines and neuronal plasticity are also reduced 
in this condition (Bambico and Belzung, 2013). Interestingly, this process is reversible. 
Administration of antidepressants will produce an increase in the number of 
new-borne neurons within the hippocampus (Malberg et al., 2000; Guilloux et al., 
2013; Sairanen et al., 2005). The observation that current antidepressant drugs 
promote adult hippocampal neurogenesis provides a much stronger evidence on this 
link (Mahar et al., 2014; Zunszain et al., 2013). These findings suggest a link between 
depression and adult neurogenesis in the hippocampus and, as discussed previously, 
many antidepressants repress the activation of FoxO. In this context, it can be 
speculated that the inactivation of FoxO3a by the PI3K/Akt signaling pathway 
achieves a more potent induction of adult hippocampal neurogenesis and 
synaptogenesis.  
10. Conclusions and Prospective  
FoxOs are recently discovered transcription factors which play a role in the onset 
or duration of psychiatric disorders. Results from cellular studies and animal models 
support the idea that FoxOs are potential mediators in the pathogenesis of depression 
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(Polter et al., 2009; Wang et al., 2013; Liang et al., 2006). Given the considerations to 
target FoxO proteins as a novel therapeutic strategy for major depression, it becomes 
essential to further investigate whether specific FoxO family members should be 
targeted. Activation and upregulation of upstream molecules of FoxOs, including 
growth factors (such as BDNF, fibroblast growth factor and IGF-1), receptor tyrosine 
kinases, Akt and ERK1/2 produce beneficial effects against depression (Shi et al., 
2012; Evans et al., 2004; Krogh et al., 2014; Mikoteit et al., 2014; Musazzi et al., 
2010). In this condition, over inhibition of FoxOs through activation of its upstream 
molecules increases the risk of cancer should be taken into consideration. The roles of 
FoxO transcription factors in major depression are summarized schematically (Fig. 5). 
However, the possibility of FoxOs and their signaling pathways being potential 
therapeutic targets in depression requires considerable experimental exploration and 
validation. Their nature as transcription factors and the difficulty to target them 
directly suggest that targeting the signaling pathways rather than the FoxOs 
themselves may be preferred strategy towards efficacious therapeutic agents. At 
present, most of the information about FoxOs is derived from cellular and animal 
models. Direct data from individuals diagnosed with major depression are still in 
great need. It will be desirable that future work should be carried out to study the 
alteration of FoxOs in depressive individuals and post mortem brain tissues. Studies 
of the genetic linkage of FoxOs and depression also provide evidence to support a role 
of FoxOs in this very important area of human pathophysiology. 
 
Fig. 5. The roles of FoxOs in major depression. Chronic stress causes imbalances of 
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neurotransmitters (such as 5-HT and NE), decreased production of growth factors (such as BDNF 
and IGF-1) and hyperactivation of HPA axis. The interaction of neurotransmitters with their 
postsynaptic receptors and binding of growth factors to their receptor tyrosine kinases (RTKs)  
inactivate FoxOs through cAMP/PKA, PKC, PI3K/Akt or MEK/ERK signaling. Hyperactive HPA 
axis promotes the nuclear location and activation of FoxOs. Released glucocorticoid also bind to 
the GRE in the promoter of FoxOs and enhance the production of FoxOs. As a result, chronic 
stress leads to the activation of FoxO, which inhibits neurogenesis/synaptogenesis and promotes 
neuronal atrophy. Consequently, all of these cause behavioral manifestations related to depression. 
FoxOs have been linked to skeletal muscle atrophy and control of cardiomyocyte 
size in numerous models (Sandri et al., 2004; Skurk et al., 2005) so it is reasonable to 
speculate that the Akt-FoxO pathway may participate in neuronal atrophy, impairment 
of synaptogenesis/neurogenesis and control of brain size in depression. Currently 
there is little evidence to support this intriguing possibility, but it is worth studying the 
effect of FoxOs on the regulation of neuronal cell size and exploring the mechanisms 
of decreased cerebral volume in depressed individuals. However, there are always 
benefits and short comings to everything, what we should keep in mind is that since 
FoxOs affect cell size, there are possible unwanted side effects of targeting FoxO in 
treatment of depression, such as muscle hypertrophy. Moreover, abnormalities 
observed in major depression most commonly occur in the raphe nuclei, nucleus 
accumbens, anterior cingulated cortex, amygdala and hippocampus (Goffer et al., 
2013; Tripp et al., 2011; Underwood et al., 1999; Andrus et al., 2012), but we still 
need to elucidate whether the change of FoxOs and their related signal pathways 
could be altered in region specific manner.  
Despite the usefulness of currently available antidepressant medications, the 
limitations of both efficacy and tolerability are nonetheless evident. A better 
understanding of the underlying neurobiology and neuropathophysiology of 
depression will help us to discover novel targets for pharmacological interventions. In 
this review, we have outlined the involvement of FoxOs and related molecules in the 
pathogenesis of depression. Targeting FoxO proteins might attenuate neuronal 
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apoptosis and play a neuroprotective effects in the central nervous system, which 
might be considered beneficial to block degenerative disorders. However, whether or 
not this can yield therapeutic target and the generation of a novel class of agents for 
the treatment of major depression will depend upon further research which reveals the 
importance of FoxOs in the physiological and particular processes of major 
depression.  
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FoxOs induce cell atrophy and this effect may affect neuronal morphology 
